CEO Executive AssistantSpecialty pharmacy strategy pharma CEO engagement has grown substantially in importance as specialty products now account for more than half of pharmaceutical spending in the United States. For CEOs of companies with specialty and rare disease products, specialty pharmacy channel strategy is not an operational detail – it is a core component of commercial success and patient access. The specialty pharmacy channel determines how quickly patients get their medication, how well they are supported through the first weeks and months of therapy, and how efficiently your product navigates the prior authorization and step therapy processes that gatekeep specialty formularies.
CEOs who do not understand specialty pharmacy strategy at a level of genuine engagement risk commercial launches that underperform despite strong clinical differentiation, patient access programs that fail the patients most in need, and competitive vulnerabilities that more sophisticated specialty pharmacy strategies could have prevented.
The Specialty Pharmacy Landscape and Why It Matters Commercially
Specialty pharmacies are not simply dispensing organizations. They are care management infrastructure: they conduct benefits investigations, manage prior authorization processes, provide specialty nurse support, manage cold chain and specialty storage, and generate the data on patient behavior that shapes your commercial understanding.
The choice of which specialty pharmacy or pharmacies to work with, and how to structure those relationships, shapes the commercial performance of your product in multiple ways:
Access speed: The time from prescription to first dispense is a critical commercial metric. Patients and prescribers who wait too long for therapy will either switch to alternatives or discontinue. Specialty pharmacies with robust hub services and streamlined prior authorization support significantly reduce this access time.
Patient adherence and persistence: Most specialty products require ongoing adherence support. Specialty pharmacy nurses and patient support programs are the primary vehicles for this. The quality of your specialty pharmacy partner’s patient support capability directly affects refill rates and long-term persistence – which determines your real-world commercial performance relative to your trial efficacy.
Data: Specialty pharmacies generate prescription and dispense data that provides granular commercial intelligence: which prescribers are writing most, which patient segments are most adherent, where the prior authorization denial rates are highest. This data informs your commercial operations in real time.
Market access execution: When payers impose prior authorization requirements or step therapy policies, your specialty pharmacy network is the operational vehicle for managing those requirements. Specialty pharmacies with strong payer relationships and efficient PA management processes reduce the commercial friction that access restrictions create.
CEO Decision Points in Specialty Pharmacy Strategy
Specialty Pharmacy Selection and Contracting
For a major specialty product launch, the selection of your specialty pharmacy network – whether exclusive distribution through one or two pharmacies, limited distribution, or open distribution – is a strategic commercial decision with long-term implications.
Exclusive or limited distribution provides more control over patient experience, more concentrated patient support resources, and better data. Open distribution provides broader access but dilutes patient support capability and reduces your data intelligence.
This decision requires CEO alignment because it affects your commercial infrastructure for the life of the product, influences your relationship with the major pharmacy benefit managers who manage specialty formularies, and shapes the patient experience you are able to deliver. Your Chief Commercial Officer and Head of Market Access should present this decision with an explicit analysis of the trade-offs before launch, not as an operational default.
Patient Support Program Design
Your patient support program – the hub services, co-pay support, prior authorization assistance, and nurse support you offer patients and prescribers – is the patient access and adherence infrastructure for your specialty product. Its design determines who can actually access your product and how likely they are to stay on therapy.
The CEO’s involvement in patient support program design should concentrate on the policy dimensions: What is the co-pay support policy, and how does it affect both commercial performance and access for underinsured or uninsured patients? What nurse support model are we committing to, and is it adequately resourced? What are our commitments to patients who lose coverage?
These are not operational decisions. They are commitments that affect patients’ lives and that reflect the company’s values in ways that become visible in patient community discussions, social media, and congressional testimony. They deserve CEO review before launch.
Specialty Pharmacy Relationship Governance
Your top two to three specialty pharmacy relationships should be governed at a level appropriate to their strategic importance. For major specialty pharmacies – CVS Specialty, Walgreens Specialty, Accredo, RxCrossroads, and others that may be your primary dispensing channels – annual CEO-level relationship reviews are appropriate.
These are not vendor management meetings. They are strategic partnership reviews: how is the patient support program performing, what data are we generating, what can we do better together, and what is the access and adherence performance against commitments?
Your Head of Specialty Channel or CCO manages the ongoing relationship. The annual CEO-level session signals the importance of the relationship and addresses any strategic issues that operational management has not fully resolved.
Real-World Evidence Through the Specialty Channel
Specialty pharmacies are significant sources of real-world evidence on product performance. The data they generate – dispense rates, refill rates, prior authorization outcomes, patient-reported outcomes from nurse support calls – provides a richer picture of real-world clinical performance than any clinical trial can.
Ensure your specialty pharmacy contracts include defined data sharing provisions that give you appropriate access to this real-world evidence. This data should feed into your medical affairs and market access programs: real-world adherence data supports payer value arguments, real-world safety data supports pharmacovigilance requirements, and prescribing pattern data informs your commercial strategy.
Your medical affairs and commercial teams operationalize this data. The CEO’s role is to ensure data rights are included in specialty pharmacy contracts (a term-sheet review question, not a legal detail) and that the data infrastructure exists to make use of what the specialty channel generates.
Specialty Pharmacy and Rare Disease Products
For rare disease products with very small patient populations, specialty pharmacy strategy is even more critical and more personal. Every patient matters commercially (in a disease affecting 5,000 patients, each patient represents 0.02 percent of your commercial base), and the patient experience with your specialty pharmacy is more visible in the patient community.
Rare disease companies frequently choose single-source specialty pharmacies with deep disease-specific expertise and strong patient community relationships. The pharmacist at a rare disease specialty pharmacy may know individual patients personally and be a trusted resource in the disease community. This relationship depth is a meaningful commercial asset.
CEOs of rare disease companies should be personally familiar with their primary specialty pharmacy partner’s approach: visit their facilities, meet the patient support team, understand the patient experience the pharmacy delivers. This 4-to-6 hour investment – typically combining a facility visit with discussions with pharmacy leadership – gives you direct knowledge that shapes how you think about patient access in your commercial strategy.
The patient support infrastructure you build through your specialty pharmacy relationships directly serves the patients whose journeys you understand through the patient advocacy engagement that characterizes rare disease leadership. Ensuring those systems are connected – that the insights from patient families inform how the specialty pharmacy support program is designed – is a CEO integration opportunity that most companies leave unrealized.
Post-Launch Specialty Channel Optimization
Specialty pharmacy performance is not static. Prior authorization denial rates change as payers modify policies. Patient adherence patterns evolve as your product accumulates real-world experience. New competitors may change the access dynamics in your specialty channel.
Your commercial operations team should maintain a real-time view of specialty channel performance metrics: days from prescription to first dispense, PA approval and denial rates, 90-day and 180-day refill rates, and patient discontinuation reasons. These metrics should be part of your monthly commercial business review.
When specialty channel metrics deteriorate – dispense times lengthen, PA denials spike, adherence declines – the response may be operational (fixing a process in your hub service or specialty pharmacy partner) or strategic (addressing a payer policy change through your market access function or government affairs team). CEOs should be informed of material changes in specialty channel performance and should understand the response plan.
The pharma commercial launch infrastructure you build pre-launch includes specialty pharmacy network establishment. The ongoing management of that infrastructure is equally important and is too often treated as a decreasing priority as the product matures.
Conclusion
Specialty pharmacy strategy pharma CEO engagement is not a commercial function to be managed below the senior leadership level. For specialty and rare disease products, the specialty pharmacy channel is the patient access and adherence infrastructure that determines the real-world performance of your product in ways that clinical trial data cannot predict. CEOs who engage in specialty pharmacy strategy at the decision points that matter – network selection, patient support program design, relationship governance – build commercial programs that deliver the full potential of their products’ clinical value.
Related Reading
For further context, explore Pharma CEO Time Management for Autoimmune Disease Strategy and Biomarker-Driven Trial Management: What Pharma CEOs Must Decide and When.